6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. J of Skin [Internet]. 2023 Nov. 13 [cited 2025 May 18];7(6):s232. Available from: https://skin.dermsquared.com/skin/article/view/2337